This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soejima, H. Articles by Tsuji, I. Search for Related Content PubMed PubMed Citation Articles by Soejima, H. Articles by Tsuji, I.

Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction

Hirofumi Soejima, MD^*, Hisao Ogawa, MD^*, Hirofumi Yasue, MD^*, Koichi Kaikita, MD^*, Keiji Takazoe, MD^*, Koichi Nishiyama, MD^*, Kenji Misumi, MD^*, Shinzo Miyamoto, MD^*, Michihiro Yoshimura, MD^*, Kiyotaka Kugiyama, MD^*, Shin Nakamura, MD and Ichiro Tsuji, PhD

^* Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto, Japan
Department of Molecular and Cellular Biology, Primate Research Institute, Kyoto University, Inuyama, Aichi, Japan
Chemo-Sero Therapeutic Research Institute, Kumamoto, Japan

View larger version (16K): [in a new window]   Figure 1 Serial changes in the serum levels of angiotensin-converting enzyme (ACE) activity in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo. **p < 0.01 vs. before administration; p < 0.01 vs. placebo.

View larger version (15K): [in a new window]   Figure 2 Serial changes in the plasma levels of tissue factor (TF) antigen in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo. *p < 0.05 vs. before administration; **p < 0.01 vs. before administration; p < 0.01 vs. placebo.

View larger version (16K): [in a new window]   Figure 3 Serial changes in the plasma levels of free tissue factor pathway inhibitor (TFPI) antigen in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo.

View larger version (15K): [in a new window]   Figure 4 Serial changes in the plasma levels of monocyte chemoattractant protein-1 (MCP-1) antigen in patients treated with enalapril and placebo (mean ± SEM). Solid circle = enalapril; open circle = placebo. *p < 0.05 vs. before administration; p < 0.01 vs. placebo; p < 0.05 vs. placebo.

View larger version (17K): [in a new window]   Figure 5 The correlations between the serum angiotensin-converting enzyme (ACE) activity and plasma monocyte chemoattractant protein-1 (MCP-1) levels (A), the serum ACE activity and plasma tissue factor (TF) levels (B) and the MCP-1 and TF levels (C).